Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 2, 1998, Pages 144-149

  Leclercq, Isabelle ^a   Desager, Jean Pierre ^a   Horsmans, Yves ^a,b  

^a Louvain Medical School   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; ISONIAZID;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; INFANT; INGESTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTITUBERCULAR AGENTS; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; ISONIAZID; ISOTHIOCYANATES; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; REFERENCE VALUES;

EID: 0031696057     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90147-3     Document Type: Article

References (27)

1. Guengerich FP, Kim DH, Iwazaki M. Role of human cytochrome P450 2E1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4:168-79.
2. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992;6:724-30.
3. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-67.
4. Ronis MJJ, Lindros KO, Ingelamn-Sundberg M. The CYP2E1 subfamily. In: Ionnides C, editor. Cytochrome P450: metabolic and toxicological aspects. Boca Raton (FL): CRC Press; 1996. p. 211-39.
5. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn BS, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-9.
6. O'Shea D, Kim RB, Wilkinson GR. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 1997;43:99-103.
7. Chung FL, Morse MA, Eklind KI. New potential chemopreventive agents for lung cancer for tobacco-specific nitrosamine. Cancer Res 1992;52:2719S-22S.
8. Guo Z, Smith TJ, Thomas PE, Yang CS. Metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone as measured by DNA alkylation in vitro and its inhibition by isothiocyanates. Cancer Res 1991;51:4798-803.
9. Smith TJ, Guo Z, Thomas PE, Chung FL, Morse MA, Elkind K, et al. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes and its inhibition by isothiocyanates. Cancer Res 1990;50:6817-22.
10. Guo Z, Smith TJ, Thomas PE, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by inducible and constitutive cytochrome P450 enzymes in rats. Arch Biochem Biophys 1992;298:279-86.
11. Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther 1996;60:651-60.
12. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochrome P450 2E1 and P450 1A2. Arch Biochem Biophys 1989;271:270-83.
13. Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993; 6:511-8.
14. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-benzoquinone imine by human CYP3A4. Biochem Pharmacol 1993;45 1563-9.
15. Lucas D, Berthou F, Girre C, Poitrenaud F, Menèz JF. High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P450 2E1 activity in humans. J Chrom Biomed applications 1993; 622:79-86.
16. Sheiner LB. ELSFIT: a program for the extended least squares fit to individual pharmacokinetic data; version 3.0. San Francisco: University of California, San Francisco; 1983.
17. Chung FL, Morse MA, Eklind KI, Lewis J. Quantitation of human uptake of the anticarcinogen phenylethyl isothiocyanate after a watercress meal. Cancer Epidemiol Biomark Prevent 1992;1:383-8.
18. Peter R, Bocker R, Beaune P, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 1990;3:565-73.
19. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P450 2E1 in chlorzoxazone 6-hydroxylation. Drug Metabolism Dispos 1995;23:438-40.
20. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and caucasians. J Pharmacol Exp Ther 1996;279:4-11.
21. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994;47:1503-8.
22. Lucas D, Menèz C, Girre C, Berthou F, Bodenez P, Joannet I, et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasians subjects. Pharmacogenetics 1995;5:298-304.
23. Vesell ES, DeAngelo Seaton T, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995;5:53-7.
24. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995;5: 143-50.
25. Court MH, Von Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 1997;18:213-26.
26. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;53:643-50.
27. Gorski JC, Jones DR, Wrighton SA. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997;3:243-56.